AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
Image Source: DepositPhotos
An Introduction
The AI-powered drug discovery process is expected to grow by a compound annual growth rate of 30% between now and 2030 and that, according to Morgan Stanley, should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.
The AI-focused Drug Discovery Stocks Portfolio
The 6 AI-focused clinical-stage drug discovery currently trading on North American stock exchanges are tracked in our AI-focused Drug Discovery Stocks Portfolio. Their stock performances for the month of August are highlighted below, in descending order, along with a description of their areas of focus, their market capitalizations, their product pipeline, their latest news, analyses and commentary on each, where pertinent and an update as to how the constituents performed during the market meltdown yesterday.
- Exscientia (EXAI): UP 5.1% in August
- Absci Corporation (ABSI): No Change in August
- Schrödinger (SDGR): DOWN 5.6% in August
- Area of Focus: uses its platform to discover novel molecules which it leverages to build a pipeline of its own clinical programs in addition to selling access to its platform to other pharmaceutical firms (see details here)
- Market Capitalization: $1,500M
- Pipeline: (see here)
- Latest News, Analyses and Commentary:
- Recursion Pharmaceuticals (RXRX): DOWN 11.2% in August
- Relay Therapeutics (RLAY): DOWN 17.4% in August
- AbCellera Biologics (ABCL): DOWN 21.5% in August
Summary
On average, the 6 constituents in our AI-focused Drug Discovery Stocks Portfolio (averaging $984M in market capitalization) went DOWN 7.8% in August vs. going UP 16.1% during July.
An Update
Tech stocks plummeted yesterday (Tuesday) after the ISM manufacturing index reported August figures below consensus expectations and that raised fears about the strength of the economy and that drove down our AI-focused Drug Discovery Stocks Portfolio by 6.6% on the day.
More By This Author:
Largest Cannabis Stocks Are Down +10% In Last Two Days: Here's Why
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
Our American Cannabis MSO Portfolio Was Down 6% Last Week
Disclosure: None
This article has been composed with the exclusive application of the human intelligence (HI) of the author. No artificial intelligence (AI) technology has been deployed. ...
moreComments
![](/images/tinyMceCommentImg.png)